Lantheus Gets FDA CRL for LNTH-2501; No Safety or Efficacy Concerns Raised
The delay is due to manufacturing issues at a third-party facility, with no safety or clinical data concerns.
/ 220 items
#andre↓
Ardelyx Suffers Legal Setback as Appeals Court Confirms XPHOZAH in Medicare Bundle
Ardelyx shares fell after losing a court case on Xphozah Medicare coverage, moving drug into bundled payments, hurting revenue outlook.
BTIG Bullish on Robinhood: Launches Coverage with $125 Target, Citing Long-Term Compounding Power
BTIG is bullish on Robinhood, seeing strong growth, young users, rising trading activity, and a $125 price target.
Moderna Shares Surge as Oncology Pipeline Ignites Investor Optimism
Piper Sandler raised its price target on Moderna from $69 to $77, maintaining an Overweight rating. Strong momentum in the oncology pipeline is fueling the rally.
Capricor Shares Fall as FDA Schedules Advisory Committee for Deramiocel
Capricor Therapeutics stock fell after the Food and Drug Administration set a July 29 review of its DMD therapy; a decision is due Aug. 22.
JPMorgan Upgrades Replimune to Overweight as FDA Sets Late-July Advisory Committee for RP1
Replimune receives FDA priority review for RP1 in advanced melanoma with August 2, 2026 PDUFA date.